30 results
8-K
EX-99.1
TYRA
Tyra Biosciences Inc
9 May 24
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
4:08pm
doses of TYRA-300 to support children with achondroplasia. TYRA expects that the primary objective of this study will be to assess safety … ) continued to
advance. The study is a multi-center, open label study designed to evaluate the safety, tolerability, and PK of TYRA-200 and determine
8-K
EX-99.1
TYRA
Tyra Biosciences Inc
19 Mar 24
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
4:05pm
of this study will be to assess safety and tolerability in children with achondroplasia and determine the dose(s) for further development. TYRA also expects … and Other Advanced Solid Tumors) (NCT06160752) is a multi-center, open label study designed to evaluate the safety, tolerability, and PK of TYRA-200
8-K
03avdky7rd
1 Feb 24
Other Events
5:24pm
8-K
rmbquuyqml8uze
22 Dec 23
Other Events
9:00am
8-K
EX-99.1
vsp3xv55ea un
7 Nov 23
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
4:07pm
8-K
EX-3.2
8i0 hmp2seov6br
26 Oct 23
Amendments to Articles of Incorporation or Bylaws
4:50pm
8-K
EX-3.1
x7yqq01 iv45xa
26 Oct 23
Amendments to Articles of Incorporation or Bylaws
4:50pm
8-K
EX-99.1
lib6yh6
10 Aug 23
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
4:21pm
8-K
EX-99.1
zo7uh9nfjadi 9un
4 May 23
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
4:08pm
10-K
EX-10.15
aj4gbz dytzi3d8n3ij
3 Mar 22
Annual report
4:31pm
10-K
y566d48 o60ch
3 Mar 22
Annual report
4:31pm